Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$4.26
$4.22
$2.06
$4.50
$370.71M1.181.51 million shsN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.69
-0.6%
$1.81
$1.32
$2.72
$248.27M1.71191,365 shs64,776 shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$54.99
$54.93
$14.91
$55.19
$1.34B0.03931,731 shsN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.00%0.00%0.00%+6.77%+93.64%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+1.19%+3.03%-8.60%+13.33%-13.27%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%0.00%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.5221 of 5 stars
1.20.00.04.21.60.00.0
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.9816 of 5 stars
3.51.00.00.00.60.00.0
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.33
Hold$4.331.72% Upside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00314.20% Upside
Lannett Company, Inc. stock logo
LCI
Lannett
0.00
N/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.50∞ Upside
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$41K9,041.59N/AN/A($0.47) per share-9.06
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M48.02N/AN/A$1.05 per share1.61
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$300K4,476.00N/AN/A$6.16 per share8.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$51.85M-$1.29N/AN/AN/AN/A-659.07%8/11/2025 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/A

Latest CKPT, MDNA, SRRA, LCI, and IMMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/A
0.29
0.29
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.02
21.27
21.27

Institutional Ownership

CompanyInstitutional Ownership
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
22.00%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
12.38%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
99.30%

Insider Ownership

CompanyInsider Ownership
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.10%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
33.10%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
44.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
1087.02 million47.81 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
10924.42 million13.65 millionOptionable

Recent News About These Companies

New cancer treatment center breaks ground in Redding
Anemia of Inflammation
Sierra Oncology Inc.
2014 GMC Sierra 1500 specs & colors
2017 GMC Sierra 1500
Safety in Radiation Oncology (SAFRON)
2024 GMC Sierra 2500HD
Sierra Coupon for October
Compare 6 trims on the 2021 GMC Sierra 1500

New MarketBeat Followers Over Time

Media Sentiment Over Time

Checkpoint Therapeutics stock logo

Checkpoint Therapeutics NASDAQ:CKPT

$4.26 0.00 (0.00%)
As of 05/30/2025

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.69 -0.01 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 +0.05 (+3.02%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Lannett stock logo

Lannett NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

Medicenna Therapeutics stock logo

Medicenna Therapeutics NASDAQ:MDNA

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Sierra Oncology stock logo

Sierra Oncology NASDAQ:SRRA

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.